# Empagliflozin

## Jardiance 25mg

| 藥物代碼 | OJAR2 |
| :--- | :--- |
| 適應症 | Diabetes mellitus, type 2 |
| 副作用 | &gt;10%: Endocrine & metabolic: Hypoglycemia \(combination therapy with insulin: 28%, severe hypoglycemia: &lt;=1%; combination therapy with metformin and a sulfonylurea: 12% to 16%; combination therapy with metformin: 1% to 2%\)Genitourinary: Urinary tract infection \(9%; females: 18%; males: 4%\), increased urine output \(includes polyuria, pollakiuria, nocturia: 3%\)1% to 10%:Endocrine & metabolic: Increased LDL cholesterol \(5% to 7%\), dyslipidemia \(4%\), increased thirst \(including polydipsia: 2%\)Gastrointestinal: Nausea \(2%\)Hematologic & oncologic: Increased hematocrit \(3% to 4%\)Infection: Genitourinary fungal infection \(4%; females: 5% to 6% \[includes bacterial vaginosis, cervicitis, vulvitis, vulvovaginal candidiasis, vulvovaginal infection, vulvovaginitis\]; males: 2% to 3% \[includes balanitis, balanoposthitis, genitourinary fungal infection, penile infection, scrotal abscess\]\) |
| 禁忌 | History of serious hypersensitivity to empagliflozin or any component of the formulation; severe renal impairment \(eGFR &lt;30 mL/minute/1.73 m2\), end-stage renal disease \(ESRD\), or dialysis |
| 懷孕用藥危分級 | 尚未確立 |
| 孕期用藥建議 | No \(Limited\) Human Data - animal data suggest low risk |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity\(Mother\) 無\(很少\)資料 - 避免使用\(母體\) |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | AC, AC15, P1, P2, P3, P4, PC, PO |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | N/A |

